Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515175 · ClinicalTrials.gov registry record · Phase 2
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
A Phase 2 study of Genital Herpes Simplex Type 2, sponsored by Genocea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 8
- Study locations
NCT02515175 is a Phase 2 study of Genital Herpes Simplex Type 2 that has completed, run by Genocea Biosciences. The registered enrollment target is 131 participants, below the 256-participant average among 3 other Genital Herpes Simplex Type 2 trials with a reported enrollment target (49% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT02515175, a Phase 2 study of Genital Herpes Simplex Type 2, has completed, sponsored by Genocea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study evaluates the reduction in viral shedding after vaccination with a new formulation of GEN-003 in subjects with genital HSV-2 infection. Two-thirds of the participants will receive GEN-003, one-third will receive placebo.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Matrix-M2
- BIOLOGICAL GEN-003
Study Locations (8)
California
- Medical Center for Clinical Research - San Diego
- Quest Clinical Research - San Francisco
Alabama
- University of Alabama-Birmingham - Birmingham
Massachusetts
- The Fenway Institute - Boston
North Carolina
- University of North Carolina - Chapel Hill - Chapel Hill
Ohio
- Cincinnati Childrens Hospital - Cincinnati
Texas
- Tekton Research - Austin
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02515175
The ClinicalTrials.gov registry entry for NCT02515175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 3 other Genital Herpes Simplex Type 2 trials with a reported enrollment target (49% lower). The listed sponsor is Genocea Biosciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Genital Herpes Simplex Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02515175 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02515175 about?
NCT02515175 is a clinical study titled "Evaluating New Formulation of Therapeutic HSV-2 Vaccine". This study evaluates the reduction in viral shedding after vaccination with a new formulation of GEN-003 in subjects with genital HSV-2 infection. Two-thirds of the participants will receive GEN-003, one-third will receive placebo.
What is the current status of trial NCT02515175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2015-11. Estimated completion is 2017-05-25.
What conditions does trial NCT02515175 study?
This clinical trial studies the following conditions: Genital Herpes Simplex Type 2.
What interventions are being tested in trial NCT02515175?
The interventions under investigation include: Placebo (DRUG), Matrix-M2 (BIOLOGICAL), GEN-003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02515175?
This trial is sponsored by Genocea Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02515175 being conducted?
This trial has 8 study locations across Alabama, California, Massachusetts, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genital Herpes Simplex Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
COMPLETED · Phase 2
-
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
ACTIVE NOT RECRUITING · Phase 1
-
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.